Buy, Sell or Hold: Tempest Therapeutics, Inc. (TPST-Q)

Home

Daily Stock Opinions and Ratings

Tempest Therapeutics, Inc. (TPST-Q)

7.67

+1.24 (19.19%)

as of Jul 25, 2025, 7:34:02 pm Market Open.

0 watching

Nervous markets await Nvidia

Tempest Therapeutics, Inc.(TPST-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Tempest Therapeutics, Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Tempest Therapeutics, Inc.(TPST-Q) Frequently Asked Questions

What is Tempest Therapeutics, Inc. stock symbol?

Tempest Therapeutics, Inc. is a American stock, trading under the symbol TPST-Q on the NASDAQ (TPST). It is usually referred to as NASDAQ:TPST or TPST-Q

Is Tempest Therapeutics, Inc. a buy or a sell?

In the last year, there was no coverage of Tempest Therapeutics, Inc. published on Stockchase.

Is Tempest Therapeutics, Inc. a good investment or a top pick?

Tempest Therapeutics, Inc. was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Tempest Therapeutics, Inc..

Why is Tempest Therapeutics, Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Tempest Therapeutics, Inc. worth watching?

In the last year 0 stock analysts on Stockchase covered Tempest Therapeutics, Inc.. The stock is worth watching.

What is Tempest Therapeutics, Inc. stock price?

On 2025-07-25, Tempest Therapeutics, Inc. (TPST-Q) stock closed at a price of $7.67.

Most Recent Experts

Brian Madden

First Avenue Investment Counsel

John Zechner

J. Zechner & Assoc

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.